
Opinion|Videos|July 2, 2024
Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- A subcutaneous form of ocrelizumab may come to market later this year. How will you incorporate this into your treatment algorithms?
- Will payers evaluate coverage decisions for this therapy differently than the intravenous form?
Advertisement
Related to this article

A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.

During OncoVenture, Careology leaders described how their platform supports patients receiving CAR T-cell therapy at home in Ohio, extends Mayo Clinic’s reach in rural Florida, and powers payer care navigation.

John Elliott, of Reimagine Care, outlined a model that pairs AI-supported triage with oncology-trained nurses, and the CEO of a large Texas practice described how the partnership has grown to include patients receiving CAR T-cell therapy.
Advertisement
Advertisement
Trending on AJMC
1
Health Equity & Access Weekly Roundup: November 20, 2026
2
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
3
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
4
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
5


